论文部分内容阅读
The purpose of the present work was to evaluatethe clinical efficacy and the mechanism of Yi-qiHuo-xue Injection(YHI 益气活血注射液)in treat-ment of coronary heart disease.YHI consists ofGinseng,Astragalus and Angelicae Sinensis.(人参黄芪,当归).The 10% dextrose serves as a pla-cebo.The results were as follows:1.the frequencyand severity of angina episodes were reduced by90.63%;2.the isehemic ST-T in ECG was improvedin 56.25% of eases;3.the tolerance to treadmillexercise was increased from 348,50 to 505.50 M.;4.the left ventricular function was strengthened,PEP/LVET ratio reduced from 0.45 to 0.36,the activityof(Na+-K+)ATPase in myocardial cell membraneof rats inhibited by 19.2%;5.the blood viscosity anderythrocyte electrophoretic time lowered;6.theadhesion and aggregation of platelet in patients withCHD were inhibited by 27% and 59.4% respectively;7.the plasma TXB_2 level in CHD was reduced from260.28±164.4 to 139.29±57.01 pg/ml;8.the plasma6-keto-PGF_(1α) level in CHD was increased from33.45±22.5 to 57.48±13.1 pg/ml,and in rats from185.77 to 366.33 pg/ml.The differences were allstatistically significant(P<0.05-0.01)in comparisonwith the placebo group.
The purpose of the present work was to evaluate the clinical efficacy and the mechanism of Yi-qi Huo-xue Injection in treat-ment of coronary heart disease. NYHI of Ginseng, Astragalus and Angelicae Sinensis. (Ginseng Astragalus , Angelica). 10% dextrose serves as a pla-cebo.The results were as follows: 1.the frequency and severity of angina episodes were reduced by90.63%; 2.the isehemic ST-T in ECG was improvedin 56.25% of The left ventricular function was strengthened, PEP / LVET ratio reduced from 0.45 to 0.36, the activity of (Na + -K +) ATPase in myocardial cell membrane of rats inhibited by 19.2%; 5. the blood viscosity anderythrocyte electrophoretic time lowered; 6. theadhesion and aggregation of platelet in patients with CHD were inhibited by 27% and 59.4% respectively; 7. the plasma TXB_2 level in CHD was reduced from 260.28 ± 164.4 to 139.29 ± 57.01 pg / ml; 8. the plasma6-keto-PGF_ (1α) level in CHD were increased from 33.45 ± 22.5 to 57.48 ± 13.1 pg / ml, and in rats from 185.77 to 366.33 pg / ml. The differences were all statistically significant (P <0.05-0.01) in comparisonwith the placebo group.